News Releases

February 3, 2017

RepliCel Appoints Corporate Executive, Hugh Rogers to its Board of Directors
VANCOUVER, BC – February 3, 2017 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (“RepliCel” or the “Company”) is pleased to announce the... Read full article

January 4, 2017

RepliCel CEO Provides 2017 Forecast
After a year of restructuring, RepliCel poised for multiple clinical trial data announcements and completion of medical device prototypes VANCOUVER, BC – January 5,... Read full article

November 1, 2016

RepliCel Life Sciences Announces Closing of Private Placement
Completed Financing Positions RepliCel Through Upcoming Milestones  VANCOUVER, BC – October 31, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”) (OTCQB: REPCD)... Read full article

October 7, 2016

RepliCel Life Sciences Amends Terms of Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC – October 7, 2016 – RepliCel... Read full article

September 27, 2016

RepliCel Announces Debt Settlement
VANCOUVER, BC – September 27, 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCD) (TSXV: RP) (Frankfurt: P6P2), (“RepliCel” or the “Company”), a clinical-stage regenerative... Read full article

September 26, 2016

RepliCel Provides Update on Shiseido License and Co-Development for RCH-01
VANCOUVER, BC – September 26 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCD) (TSXV: RP) (Frankfurt: P6P2), (“RepliCel” or the “Company”), a clinical-stage regenerative... Read full article

September 14, 2016

RepliCel Life Sciences Announces Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Funding proceeds anticipated to see RepliCel through several... Read full article

August 9, 2016

Replicel Life Sciences Share Consolidation Approved
Capital Structure Restructuring Expected to Lead to Financing and Milestones  VANCOUVER, BC – August 9, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the... Read full article

July 22, 2016

Replicel Life Sciences Continues Restructuring with Share Structure Consolidation
VANCOUVER, BC – July 22, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”) (OTCQB: REPCF) (TSXV: RP) (Frankfurt: P6P1), a clinical stage... Read full article

July 21, 2016

RepliCel’s Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan
VANCOUVER, BC – July 21, 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (Frankfurt: P6P1), (“RepliCel” or the “Company”), a clinical-stage regenerative... Read full article